Evaluation of O6-Benzylguanine−Potentiated Topical Carmustine for Mycosis Fungoides | Zendy

Joselin D. Tacastacas | Zendy; Derek V. Chan | Zendy; Sean Carlson | Zendy; Stanton L. Gerson | Zendy; Afshin Dowlati | Zendy; Pingfu Fu | Zendy; Kurt Q. Lu | Zendy; Sarah Groft | Zendy; Julie Rosenjack | Zendy; Kord Honda | Zendy; Thomas S. McCormick | Zendy; Kevin D. Cooper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of O⁶-Benzylguanine−Potentiated Topical Carmustine for Mycosis Fungoides

Author(s) -

Joselin D. Tacastacas,

Derek V. Chan,

Sean Carlson,

Stanton L. Gerson,

Afshin Dowlati,

Pingfu Fu,

Kurt Q. Lu,

Sarah Groft,

Julie Rosenjack,

Kord Honda,

Thomas S. McCormick,

Kevin D. Cooper

Publication year - 2017

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2016.5793

Subject(s) - carmustine , mycosis fungoides , medicine , adverse effect , stage (stratigraphy) , gastroenterology , clinical trial , chemotherapy , lymphoma , pharmacology , cyclophosphamide , paleontology , biology

In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research